Insider Selling at Mesa Laboratories as Institutions Adjust Holdings

On June 18, 2026, Brian David Archbold, the Senior Vice President of Operations at Mesa Laboratories, Inc. (NasdaqGS: MLAB), sold 2,480 shares of the company. This insider transaction occurred as the stock traded around $93.23.

Insider Buying and Selling at Mesa Laboratories, Inc.

Brian Archbold, SVP Operations, sold 2,480 shares on June 18, 2026. This transaction was not part of a pre-planned trading program. On the same day, CFO John Sakys purchased 2,282 shares at $95.10, while CAO Lyndsey Elizabeth Crennen sold 233 shares.

Other Institutional Activity in Mesa Laboratories

Several institutional investors made changes to their holdings in Mesa Laboratories. LONG PATH PARTNERS LP increased its stake by 178,360 shares, holding a total of 405,583 shares valued at approximately $35.9 million. In contrast, BlackRock, Inc. trimmed its position by 4,815 shares, leaving it with 393,851 shares worth about $34.8 million. Boston Partners boosted its holdings by 55,335 shares, bringing its total to 268,711 shares valued at $23.8 million. Meanwhile, Select Equity Group, L.P. added 29,450 shares, resulting in 235,885 shares worth around $20.9 million. Vanguard Capital Management LLC opened a new position with 232,643 shares valued at about $20.6 million.

Mesa Laboratories, Inc. Stock Down 27.7%

Shares of Mesa Laboratories, Inc. traded near $93.23 on Tuesday. The company has a market cap of approximately $515.1 million and a P/E ratio of 77.0, with a forward P/E of 7.6. The stock's 52-week range is between $55.45 and $113.99, with a 50-day moving average of $101.99 and a 200-day moving average of $84.97. Mesa Labs has a current ratio of 1.72 and a quick ratio of 1.17, with a debt-to-equity ratio of 90.65.

Recent Earnings

Mesa Laboratories reported revenues of $249.13 million, marking a 2.6% growth. The company achieved an EPS of $1.21, with a net margin of 2.7% and a return on equity of 3.9%. The next earnings report is expected on August 5, 2026.

Dividend

Mesa Laboratories offers an annual dividend of $0.64 per share, yielding 0.67%. The dividend payout ratio is approximately 52.9%.

Analysts Set New Price Targets

Wells Fargo maintained its 'hold' rating on Mesa Laboratories with a price target of $94.0 as of February 4, 2026. Evercore ISI has consistently rated the stock as a 'buy' with a target of $106.0. The consensus target price is $112.0, based on two analyst opinions.

About Mesa Laboratories

Mesa Laboratories, Inc., headquartered in Lakewood, Colorado, designs and manufactures quality control and life sciences tools. It operates in sectors like sterilization and disinfection control, clinical genomics, biopharmaceutical development, and calibration solutions. The company provides products and services globally, serving various industries, including pharmaceuticals and healthcare.

Bottom Line

Insider trading activity at Mesa Laboratories, including the sale by SVP Brian Archbold, reflects ongoing shifts in company stock ownership. Investors track such changes for insights into company performance and market sentiment. Institutional activity also suggests varied confidence levels among major shareholders. As always, these filings provide a historical snapshot and may not indicate current positions.